Building a Better Understanding in Asthma Management: Best Practices for
Treatment and Control

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2019 to January 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals

Characterized by reversible airway obstruction, airway hyper-responsiveness, and the production of specific inflammatory mediators, asthma affects approximately 26 million Americans. Greater attention is needed in appropriate management of this condition to help patients achieve asthma control. There are various problems that affect adherence amongst asthma patients to include inadequate physician-patient communication, absence of a clear treatment plan, and lack of managing lifestyle/environmental triggers. Traditional pharmacologic treatment includes the use of inhaled corticosteroids (ICS), long-acting beta-2 agonists, theophylline, and leukotriene modifiers. Several new therapies, such as anti-immunoglobulin E and anti-IL- antibodies, are aiming to control and treat asthma, which could improve the lives of patients with uncontrolled persistent asthma. More recent studies and clinical data show that new treatments and injectables are set to become available and could help improve lung function, reduce severe exacerbations, and decrease rescue bronchodilator use. Novel biologics are also in development to target inflammatory mediators that explore multiple phenotypes and endotypes of severe asthma. With all the recent advances in therapeutic options, a personalized treatment plan that combines pharmacological treatment and lifestyle modification needs to be integrated into the management strategy.

Upon completion of this activity, participants will be able to:

  • Analyze recent clinical trial data and the current guidelines for a better understanding of asthma management and control, including potential biomarkers

  • Discuss the best practices for the diagnosis of asthma to assess severity, taking into account the heterogeneous disease state, to reduce the high burden of disease and improve outcomes

  • Assess the latest advances in treatment paradigms for patients with asthma, including new and emerging biologic therapies and medications

  • Evaluate effective pharmacotherapy regimens based on severity, sub-type, phenotype, and/or endotype to establish a consistent approach for long-term control and management of asthma

  • Examine evidence-based strategies and self-management of asthma including proper inhaler use and technique to ensure correct delivery of medication and improved patient outcomes

Faculty: Michael E. Wechsler, MD, MMSc
Professor, Department of Medicine
Co-Director, The Cohen Family Asthma Institute
Division of Pulmonary, Critical Care and Sleep Medicine
Director, Asthma Program
National Jewish Health


Dr. Wechsler serves as a consultant for AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi, and Teva. He has received research/grant support from AstraZeneca, Novartis, Regeneron, Sanofi, and Teva. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue